Millions rely on Medicare Part D, but many prescription drugs won't be covered in 2026. See which meds are excluded, why, and how to avoid costly surprises.

Coverage of several self-administered DMARDs declined across Medicare Part D plans between 2022 and 2026, with differential coverage noted across plan types.

Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the popular weight-loss drugs ...

Aetna’s 2026 Medicare plans bring expanded benefits, $0 premium options, and enhanced prescription coverage to millions of eligible Americans. With choices ranging from Medicare Advantage to Medigap, ...

CVS Health reported first quarter net income of more than $2.9 billion as costs slowed for subscribers of the Aetna health ...

Learn who qualifies for Medicare’s GLP-1 Bridge, when $50 Wegovy and Zepbound access begins, and key rules beneficiaries need ...

Aetna®, a CVS Health® company (NYSE: CVS), is setting the pace for prior authorization reform, moving faster and further to simplify access to care for patients and providers.

Please provide your email address to receive an email when new articles are posted on . Uneven coverage and exclusions of certain DMARDs represent barriers to care. Rheumatologists should be aware ...

Optum Rx has announced that it is replacing the traditional pharmacy benefit manager model with a transparent, fee‑based ...

Common assumptions about Part B, IRMAA and FEHB coordination can obscure how coverage and costs actually play out over time.

An analysis of two markets shows some commercial plans provide the lowest estimated yearly costs, but federal annuitants must ...

Managing finances on a fixed income can be challenging, particularly when insurance plans reset and deductibles and other out-of-pocket costs must be paid upfront. For individuals with ...